Lutetium-177 PSMA radionuclide treatment (Lu-PSMA) is another treatment for cutting edge prostate disease. Lu-PSMA is a radioactive particle that explicitly appends to cells with high measures of PSMA on the outside of the cells. This enables the radioactivity to be conveyed primarily to the prostate malignancy cells wherever they have spread, while saving most typical tissues. Past little investigations of Lu-PSMA indicated promising movement in patients with cutting edge prostate malignant growth.

This randomized investigation will contrast Lu-PSMA and a kind of chemotherapy called cabazitaxel, which is the standard treatment for cutting edge prostate malignant growth when different medicines have quit working. A large portion of the members will get Lu-PSMA and half will get cabazitaxel. This investigation will give additional data about the dangers and advantages of Lu-PSMA contrasted and cabazitaxel in men with prostate malignancy. We intend to enlist 200 members in the investigation in Australia.

TheraP is an association between ANZUP Cancer Trials Group and the Prostate Cancer Foundation of Australia (PCFA) with help from the Australian Nuclear Science and Technology Organization (ANSTO), Endocyte, It’s a Bloke Thing, Movember and CAN4CANCER.

Inspired by this preliminary? Print off the TheraP preliminary subtleties from the Australian and New Zealand Clinical Trials Registry and take to your GP.

As often as possible made inquiries

What is Lutetium and how can it work?

Numerous prostate tumors have a substance on their phone surface called prostate explicit layer antigen (PSMA). Lu-PSMA is a radioactive atom that, after infusion into a vein, explicitly appends to cells with high measures of PSMA on the outside of the cells. This enables the radioactivity to be conveyed for the most part to the prostate malignant growth cells wherever they have spread and to assault those disease cells.

Will this preliminary be reasonable for anybody with prostate disease?

No. This preliminary is pointed explicitly at men with prostate disease that has spread to different pieces of the body and has kept on developing regardless of standard treatment (counting hormonal treatment and past docetaxel chemotherapy), and where you and your specialist have concurred that the following best advance is treatment with another chemotherapy tranquilize called cabazitaxel.

What is the point of this preliminary?

The motivation behind this investigation is to contrast Lu-PSMA and cabazitaxel for men with prostate disease that has spread to different pieces of the body and has kept on developing regardless of standard treatment, including hormonal treatment and past docetaxel chemotherapy. We need to know how Lu-PSMA thinks about against cabazitaxel as far as contracting the malignant growth, improving agony, deferring the time until the disease develops once more, impacts on personal satisfaction, security, and to what extent men get by after the treatment.